Application | Comment | Organism |
---|---|---|
medicine | statin treatment reduces ACAT2 activity in human liver and this effect, in combination with a reduced ApoE expression, may contribute to the favorable lowering of VLDL cholesterol seen in addition to the LDL lowering during statin treatment | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
microsome | - |
Homo sapiens | - |
- |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
50000 | - |
determined by SDS-PAGE and Western Blot analysis | Homo sapiens |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
acyl-CoA + cholesterol | Homo sapiens | - |
CoA + cholesterol ester | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
liver | - |
Homo sapiens | - |
Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|
0.0000293 | - |
ACAT2 activity, effect on ChSI on hepatic ACAT2 expression, high cholesterol synthesis inhibition, high ChSI | Homo sapiens |
0.0000333 | - |
ACAT2 activity, effect on ChSI on hepatic ACAT2 expression, low cholesterol synthesis inhibition, low ChSI | Homo sapiens |
0.0000377 | - |
ACAT2 activity, effect on cholesterol synthesis inhibition on hepatic ACAT2 expression, placebo | Homo sapiens |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
acyl-CoA + cholesterol | - |
Homo sapiens | CoA + cholesterol ester | - |
? |
Synonyms | Comment | Organism |
---|---|---|
ACAT2 | - |
Homo sapiens |
acyl-CoA:cholesterol acyltransferase 2 | - |
Homo sapiens |